Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 343861 - 343880 out of 488720 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Norway | (L01FF05) atezolizumab | Tecentriq 1 200 mg | 20 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 1 200 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | RocheRegistrationGmbH |
| Norway | (L01FF05) atezolizumab | Tecentriq 840 mg | 14 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 840 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | RocheRegistrationGmbH |
| Norway | (L01FF05) atezolizumab | Tecentriq 840 mg | 14 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 840 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | OrifarmAS |
| Norway | (L01FF05) atezolizumab | Tecentriq 1 875 mg | 15 ml, Hetteglass, Injeksjonsvæske, oppløsning, 1 875 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | RocheRegistrationGmbH |
| Norway | (L01FF06) cemiplimab | Libtayo 350 mg | 7 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 350 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Squamous Cell | OrifarmAS |
| Norway | (L01FF07) dostarlimab | Jemperli 500 mg | 500 mg, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 500 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Endometrial Neoplasms | OrifarmAS |
| Norway | (L01FX14) polatuzumab vedotin | Polivy 30 mg | 30 mg, Hetteglass, Pulver til konsentrat til infusjonsvæske, oppløsning, 30 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Lymphoma, B-Cell | RocheRegistrationGmbH |
| Norway | (L01FX27) epcoritamab | Tepkinly 48 mg | 0.8 ml, Hetteglass, Injeksjonsvæske, oppløsning, 48 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Lymphoma, Large B-Cell, Diffuse | AbbVieDeutschlandGmbH&Co |
| Norway | (L01FX32) elranatamab | Elrexfio 40 mg/ml | 1.9 ml, Hetteglass, Injeksjonsvæske, oppløsning, 40 mg/ml , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Multiple Myeloma | PfizerEuropeMAEEIG |
| Norway | (L01FX32) elranatamab | Elrexfio 40 mg/ml | 1.1 ml, Hetteglass, Injeksjonsvæske, oppløsning, 40 mg/ml , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Multiple Myeloma | PfizerEuropeMAEEIG |
| Norway | (L01FY01) pertuzumab and trastuzumab | Phesgo 1 200 mg/600 mg | 15 ml, Hetteglass, Injeksjonsvæske, oppløsning, 1 200 mg/600 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Breast Neoplasms | OrifarmAS |
| Norway | (L01FY01) pertuzumab and trastuzumab | Phesgo 1 200 mg/600 mg | 15 ml, Hetteglass, Injeksjonsvæske, oppløsning, 1 200 mg/600 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Breast Neoplasms | RocheRegistrationGmbH |
| Norway | (L01FY01) pertuzumab and trastuzumab | Phesgo 600 mg/600 mg | 10 ml, Hetteglass, Injeksjonsvæske, oppløsning, 600 mg/600 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Breast Neoplasms | RocheRegistrationGmbH |
| Norway | (L01FY01) pertuzumab and trastuzumab | Phesgo 600 mg/600 mg | 10 ml, Hetteglass, Injeksjonsvæske, oppløsning, 600 mg/600 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Breast Neoplasms | OrifarmAS |
| Norway | (L01XD04) aminolevulinic acid | Gliolan 30 mg/ml | 1.5 g, Flaske av glass, Pulver til mikstur, oppløsning, 30 mg/ml , Flaske av glass | Retail price with vat |
$0-0 |
$0-0 |
Glioma | photonamicGmbH&Co.KG |
| Norway | (L01XG01) bortezomib | Bortezomib Accord 2,5 mg/ml | 1.4 ml, Hetteglass, Injeksjonsvæske, oppløsning, 2,5 mg/ml , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Multiple Myeloma | AccordHealthcareS.L.U. |
| Norway | (L01XG01) bortezomib | Bortezomib Stada 2,5 mg/ml | 1.4 ml, Hetteglass, Injeksjonsvæske, oppløsning, 2,5 mg/ml , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
n/a | StadaArzneimittelAG |
| Norway | (L01XG01) bortezomib | Bortezomib Fresenius Kabi 3,5 mg | 3.5 mg, Hetteglass, Pulver til injeksjonsvæske, oppløsning, 3,5 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Multiple Myeloma | FreseniusKabiDeutschlandGmbH |
| Norway | (L01XG02) carfilzomib | Kyprolis 10 mg | 10 mg, Hetteglass, Pulver til infusjonsvæske, oppløsning, 10 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Multiple Myeloma | AmgenEuropeB.V. |
| Norway | (L01XG02) carfilzomib | Kyprolis 30 mg | 30 mg, Hetteglass, Pulver til infusjonsvæske, oppløsning, 30 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Multiple Myeloma | AbacusMedicineA/S |
Pages
